August 2018 PBAC special meeting - brief outcome now available

Page last updated: 28 September 2018

The brief outcome from the August 2018 special meeting regarding PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types is now available.